Allon Therapeutics Inc. (TSX:NPC) is a Canadian biotechnology company developing drugs that protect against neurodegenerative conditions such as Alzheimer’s disease, mild cognitive impairment, traumatic brain injury, stroke, multiple sclerosis and neuropathy. Allon’s drug discovery platform has resulted in the development of a unique class of peptide compounds that has demonstrated broad efficacy in numerous pre-clinical models of neurodegenerative diseases.